Drug intelligence / Profile preview

SND 462-AM

Development stage: Preclinical
Lead developer: Floratek Pharma
Modality: Small Molecules
Administration: Parenteral

Overview

SND 462-AM is a small molecule inhibitor of Right Open Reading Frame Kinase 2 (RIOK2), currently in development by Floratek Pharma for the treatment of colorectal cancer. RIOK2 is an atypical kinase that plays a critical role in ribosome biogenesis and cell cycle progression; its inhibition is hypothesized to disrupt protein synthesis and induce apoptosis in malignant cells. The program is currently in the IND-enabling phase of preclinical development.

Other names: SND 462-AMSND462-AMSND-462-AM

Targets

RIOK2 (Right open reading frame kinase 2)

Beyond the preview

Go deeper on SND 462-AM.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SND 462-AM.

Explore the full profile